180 related articles for article (PubMed ID: 34144488)
1. Olaparib enhances curcumin-mediated apoptosis in oral cancer cells by inducing PARP trapping through modulation of BER and chromatin assembly.
Molla S; Chatterjee S; Sethy C; Sinha S; Kundu CN
DNA Repair (Amst); 2021 Sep; 105():103157. PubMed ID: 34144488
[TBL] [Abstract][Full Text] [Related]
2. PARP inhibitor Olaparib Enhances the Apoptotic Potentiality of Curcumin by Increasing the DNA Damage in Oral Cancer Cells through Inhibition of BER Cascade.
Molla S; Hembram KC; Chatterjee S; Nayak D; Sethy C; Pradhan R; Kundu CN
Pathol Oncol Res; 2020 Oct; 26(4):2091-2103. PubMed ID: 31768967
[TBL] [Abstract][Full Text] [Related]
3. Combination of talazoparib and olaparib enhanced the curcumin-mediated apoptosis in oral cancer cells by PARP-1 trapping.
Chatterjee S; Dhal AK; Paul S; Sinha S; Das B; Dash SR; Kundu CN
J Cancer Res Clin Oncol; 2022 Dec; 148(12):3521-3535. PubMed ID: 35962813
[TBL] [Abstract][Full Text] [Related]
4. PARP inhibitor BMN-673 induced apoptosis by trapping PARP-1 and inhibiting base excision repair via modulation of pol-β in chromatin of breast cancer cells.
Sethy C; Kundu CN
Toxicol Appl Pharmacol; 2022 Feb; 436():115860. PubMed ID: 34998856
[TBL] [Abstract][Full Text] [Related]
5. Talazoparib enhances the quinacrine-mediated apoptosis in patient-derived oral mucosa CSCs by inhibiting BER pathway through the modulation of GCN5 and P300.
Das C; Dash SR; Sinha S; Paul S; Das B; Bhal S; Sethy C; Kundu CN
Med Oncol; 2023 Nov; 40(12):351. PubMed ID: 37940725
[TBL] [Abstract][Full Text] [Related]
6. Olaparib enhances the Resveratrol-mediated apoptosis in breast cancer cells by inhibiting the homologous recombination repair pathway.
Sinha S; Chatterjee S; Paul S; Das B; Dash SR; Das C; Kundu CN
Exp Cell Res; 2022 Nov; 420(1):113338. PubMed ID: 36075449
[TBL] [Abstract][Full Text] [Related]
7. Combination of Resveratrol and PARP inhibitor Olaparib efficiently deregulates homologous recombination repair pathway in breast cancer cells through inhibition of TIP60-mediated chromatin relaxation.
Sinha S; Paul S; Acharya SS; Das C; Dash SR; Bhal S; Pradhan R; Das B; Kundu CN
Med Oncol; 2024 Jan; 41(2):49. PubMed ID: 38184505
[TBL] [Abstract][Full Text] [Related]
8. ABT-888 and quinacrine induced apoptosis in metastatic breast cancer stem cells by inhibiting base excision repair via adenomatous polyposis coli.
Siddharth S; Nayak D; Nayak A; Das S; Kundu CN
DNA Repair (Amst); 2016 Sep; 45():44-55. PubMed ID: 27334689
[TBL] [Abstract][Full Text] [Related]
9. Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors.
Hopkins TA; Shi Y; Rodriguez LE; Solomon LR; Donawho CK; DiGiammarino EL; Panchal SC; Wilsbacher JL; Gao W; Olson AM; Stolarik DF; Osterling DJ; Johnson EF; Maag D
Mol Cancer Res; 2015 Nov; 13(11):1465-77. PubMed ID: 26217019
[TBL] [Abstract][Full Text] [Related]
10. Targeting PARP-1 with metronomic therapy modulates MDSC suppressive function and enhances anti-PD-1 immunotherapy in colon cancer.
Ghonim MA; Ibba SV; Tarhuni AF; Errami Y; Luu HH; Dean MJ; El-Bahrawy AH; Wyczechowska D; Benslimane IA; Del Valle L; Al-Khami AA; Ochoa AC; Boulares AH
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33495297
[TBL] [Abstract][Full Text] [Related]
11. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
[TBL] [Abstract][Full Text] [Related]
12. ALC1/CHD1L, a chromatin-remodeling enzyme, is required for efficient base excision repair.
Tsuda M; Cho K; Ooka M; Shimizu N; Watanabe R; Yasui A; Nakazawa Y; Ogi T; Harada H; Agama K; Nakamura J; Asada R; Fujiike H; Sakuma T; Yamamoto T; Murai J; Hiraoka M; Koike K; Pommier Y; Takeda S; Hirota K
PLoS One; 2017; 12(11):e0188320. PubMed ID: 29149203
[TBL] [Abstract][Full Text] [Related]
13. Olaparib modulates DNA repair efficiency, sensitizes cervical cancer cells to cisplatin and exhibits anti-metastatic property.
Prasad CB; Prasad SB; Yadav SS; Pandey LK; Singh S; Pradhan S; Narayan G
Sci Rep; 2017 Oct; 7(1):12876. PubMed ID: 28993682
[TBL] [Abstract][Full Text] [Related]
14. Rationale for poly(ADP-ribose) polymerase (PARP) inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibition.
Murai J; Zhang Y; Morris J; Ji J; Takeda S; Doroshow JH; Pommier Y
J Pharmacol Exp Ther; 2014 Jun; 349(3):408-16. PubMed ID: 24650937
[TBL] [Abstract][Full Text] [Related]
15. PARP-1/2 Inhibitor Olaparib Prevents or Partially Reverts EMT Induced by TGF-β in NMuMG Cells.
Schacke M; Kumar J; Colwell N; Hermanson K; Folle GA; Nechaev S; Dhasarathy A; Lafon-Hughes L
Int J Mol Sci; 2019 Jan; 20(3):. PubMed ID: 30691122
[TBL] [Abstract][Full Text] [Related]
16. PARP Inhibitor Olaparib Causes No Potentiation of the Bleomycin Effect in VERO Cells, Even in the Presence of Pooled ATM, DNA-PK, and LigIV Inhibitors.
Perini V; Schacke M; Liddle P; Vilchez-Larrea S; Keszenman DJ; Lafon-Hughes L
Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33167404
[TBL] [Abstract][Full Text] [Related]
17. p21CDKN1A Regulates the Binding of Poly(ADP-Ribose) Polymerase-1 to DNA Repair Intermediates.
Dutto I; Sukhanova M; Tillhon M; Cazzalini O; Stivala LA; Scovassi AI; Lavrik O; Prosperi E
PLoS One; 2016; 11(1):e0146031. PubMed ID: 26730949
[TBL] [Abstract][Full Text] [Related]
18. Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint.
Lin X; Chen D; Zhang C; Zhang X; Li Z; Dong B; Gao J; Shen L
J Exp Clin Cancer Res; 2018 Jun; 37(1):129. PubMed ID: 29954437
[TBL] [Abstract][Full Text] [Related]
19. Downregulation of APE1 potentiates breast cancer cells to olaparib by inhibiting PARP-1 expression.
Ma X; Dang C; Min W; Diao Y; Hui W; Wang X; Dai Z; Wang X; Kang H
Breast Cancer Res Treat; 2019 Jul; 176(1):109-117. PubMed ID: 30989461
[TBL] [Abstract][Full Text] [Related]
20. The chromatin remodeler ALC1 underlies resistance to PARP inhibitor treatment.
Juhász S; Smith R; Schauer T; Spekhardt D; Mamar H; Zentout S; Chapuis C; Huet S; Timinszky G
Sci Adv; 2020 Dec; 6(51):. PubMed ID: 33355125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
